---
title: "Roivant Sciences (ROIV) Gets a Buy from J.P. Morgan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283225952.md"
description: "J.P. Morgan analyst Brian Cheng has maintained a Buy rating on Roivant Sciences (ROIV) with a price target of $35.00, while the stock closed at $29.83. The analyst consensus suggests a Strong Buy rating with an average price target of $34.70, indicating a potential upside of 16.33%. Piper Sandler also supports this with a Buy rating and a $40.00 price target."
datetime: "2026-04-18T12:17:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283225952.md)
  - [en](https://longbridge.com/en/news/283225952.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283225952.md)
---

# Roivant Sciences (ROIV) Gets a Buy from J.P. Morgan

In a report released yesterday, Brian Cheng from J.P. Morgan maintained a Buy rating on Roivant Sciences, with a price target of $35.00. The company’s shares closed yesterday at $29.83.

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Cheng covers the Healthcare sector, focusing on stocks such as Revolution Medicines, Protagonist Therapeutics, and Roivant Sciences. According to TipRanks, Cheng has an average return of 7.9% and a 53.93% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Roivant Sciences with a $34.70 average price target, implying a 16.33% upside from current levels. In a report released on April 16, Piper Sandler also maintained a Buy rating on the stock with a $40.00 price target.

### Related Stocks

- [ROIV.US](https://longbridge.com/en/quote/ROIV.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [PTGX.US](https://longbridge.com/en/quote/PTGX.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)
- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)
- [Dyadic International Q1 net loss narrows](https://longbridge.com/en/news/286311192.md)